CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...
NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...
The MarketWatch News Department was not involved in the creation of this content. -- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authorization is based on ...
CEO Tim Van Hauwermeiren emphasized the company’s long-term strategy with Vision 2030, aiming to reach 50,000 patients across 10 labeled indications while advancing five Phase III assets. The company ...
CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its ...
Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback